China approval for NuculaThird indication achieved in ChinaNucula has generated £1.3 billion of sales year-to-datePharmaceutical firm GSK (GSK) said it has received approval from the China Medical Products Administration for Nucula, its monoclonal antibody treatment for adults with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).It is the third indication to be approved

London stocks traded mixed on Friday, while market participants digested US jobless claims data suggesting resilience in the American economy and kept one eye on data releases due out in the afternoon.The FTSE 100 index was marginally higher, by 0.040 points, at 8,137.03. The FTSE 250 was down 70.18 points, 0.3%, at 20,501.33, and the AIM All-Share was down 0.22 points at 717.18.The Cboe UK 100 wa

Stocks in London opened in the green on Tuesday morning but not everyone is feeling the Christmas spirit, with Vistry issuing a profit warning.The FTSE 100 index opened up 21.00 points, 0.3%, at 8,123.72. The FTSE 250 was up 57.64 points, 0.3%, at 20,476.73, and the AIM All-Share was up 3.11 points, 0.4%, at 715.55.The Cboe UK 100 was up 0.3% at 815.18, the Cboe UK 250 was up 0.3% at 17,932.69, an

Analysts expect £78.5 billion in payouts£56.5 billion of buybacks this yearFTSE 100 up over 7% in 2024The latest AJ Bell Dividend Dashboard report shows FTSE 100 constituents are on course to pay £78.5 billion in ordinary dividends this year.That figure is almost flat on 2023 and well below the all-time high of £85.2 billion recorded in 2018, although analysts are penciling in a 6.5% increase

Few doubt that 2025 will be another huge year for AI, but when looking for interesting investment opportunities, investors can sometimes allow details to obscure the bigger picture. In our view, Alphabet (GOOG:NASDAQ) remains an outstanding growth business with strong AI levers to pull, currently trading a large discount to other 'Magnificent Seven' stocks.This valuation gap will, we believe, narr

Stock prices in Europe were mostly lower on Monday morning, as UK consumer confidence deteriorated while France's credit rating received a downgrade from Moody's.China's retail sales growth weakened last month, missing forecasts as demand remains muted in the world's number two economy.Retail sales expanded 3% year-on-year in November, the National Bureau of Statistics said, slowing from a 4.8% ri

The FTSE 100 index closed up on Thursday, with AstraZeneca shares rising on US FDA approval of its Imfinzi treatment.Also on Thursday, UK Prime Minister Keir Starmer promised a 'relentless focus on delivering for working people' ahead of a major speech setting out targets to measure progress on his government's plans.AJ Bell's Danni Hewson noted: 'The prime minister today said that households will

Shares in US retail titan Costco Wholesale (COST:NASDAQ) have been on an astonishing run, not just over the last 12 months but for several years before that and the shares are now trading at all-time highs.The company has consistently reported earnings ahead of expectations in recent quarters and, given the elevated share price, it may need to do so again if it is to sustain its red-hot momentum w

European indices had a mixed finish on Wednesday in the face of French political uncertainty while British Airway's owner IAG rallied on analyst support.The FTSE 100 index fell 23.60 points, 0.3%, at 8,335.81. The FTSE 250 ended up 112.41 points, 0.5%, at 21,005.15, and the AIM All-Share rose 3.13 points, 0.4%, at 738.22.The Cboe UK 100 ended down 0.4% at 836.98, the Cboe UK 250 advanced 0.6% at 1

European equities are having a 'largely positive' session on Wednesday, but the FTSE 100 stuck out a like a sore thumb, with some of its more defensive stocks in the red.The FTSE 100 index fell 18.05 points, 0.2%, at 8,341.36. The FTSE 250 added 31.42 points, 0.2%, at 20,924.16, and the AIM All-Share rose 0.75 of a point, 0.1%, at 735.84.The Cboe UK 100 lost 0.4% at 837.01, the Cboe UK 250 was up

London's stock indices closed higher on Wednesday, contrasting with broader European declines, with confidence from easing bond yields lifting housebuilders over the session.The FTSE 100 index rose 16.14 points, 0.2%, at 8,274.75. The FTSE 250 climbed 32.98 points, 0.2%, at 20,601.63, and the AIM All-Share firmed 0.81 of a point, 0.1%, at 731.40.The Cboe UK 100 advanced 0.1% at 831.73, the Cboe UK

Stock prices in London were just about in the green at midday, outperforming Paris and Frankfurt, where shares succumbed to French budget concerns and worries that the European economy could be next to fall into the cross-hairs of Donald Trump tariffs.The FTSE 100 index added 4.24 points, 0.1%, at 8,262.85 heading into Wednesday afternoon. The FTSE 250 rose 15.49 points, 0.1%, at 20,584.14, and th

SDI (SDI:AIM) 58pMarket cap: £60.6 millionThe past couple of years have seen many a growth grenade tossed at SDI (SDI:AIM) yet the company has stuck to its largely successful knitting and we expect its fortunes to significantly improve through 2025. A casual glance at the share price chart might put a quick end to investors' research into this small cap business, but that's a mistake, in our view

Stocks in London were mixed at Wednesday midday, as investors digested a hotter-than-expected consumer price growth reading in the UK, while focus across the Atlantic turns to Nvidia's earnings.The FTSE 100 index climbed just 3.66 points at 8,102.68. The FTSE 250 fell 59.75 points, 0.3%, at 20,367.87, and the AIM All-Share was up 1.04 points, 0.1%, at 725.27.The Cboe UK 100 was flat at 814.74, the

AstraZeneca CEO buys 20,000 sharesTravis Perkins CEO buys 249, 218 sharesASOS director buys £430,135 sharesPascal Soriot, CEO of pharmaceutical firm AstraZeneca (AZN) has bought 20,000 shares at £102 for a total value of £2.04 million on 15 November.Soriot's purchase comes after the pharmaceutical giant delivered earnings ahead of consensus forecasts and raised its outlook on 14 November.Over t

Stocks in London edged lower on Friday, while equities in New York dropped in early trade following some hawkish comments from the chair of the US Federal Reserve.The FTSE 100 index lost 7.58 points, 0.1%, at 8,063.61. The FTSE 250 declined 46.17 points, 0.2%, at 20,476.64, and the AIM All-Share gave back 2.24 points, 0.3%, at 727.14.For the week, the FTSE 100 slipped 0.1%, the FTSE 250 declined 0

Shares in London posted modest gains around midday on Friday despite weaker-than-expected third quarter economic growth figures.In the third quarter, UK GDP edged up 0.1%, missing the 0.2% consensus, and slowing from 0.5% seen between April and June, according to the Office for National Statistics.Industrial production also missed forecasts and the trade deficit widened, although construction outp

Stocks in London slipped at the close on Tuesday, joining the pound, which failed to pack a punch against the dollar amid political uncertainty.The FTSE 100 index slumped 99.42 points, 1.2%, at 8,025.77. The FTSE 250 closed down 295.73 points, 1.4%, at 20,427.80. The AIM All-Share fell 7.07 points, 1.0%, at 730.86.The Cboe UK 100 declined 1.2% at 805.89, the Cboe UK 250 retreated 1.6% at 17,865.50

Stocks closed higher in London on Monday, with the FTSE 100 snapping out of a four-day losing streak following a boost from UK high street banks.The FTSE 100 index rose 52.80 points, 0.7%, at 8,125.19. The FTSE 250 closed up 203.57 points, 1.0%, at 20,721.49. The AIM All-Share gained 3.57 points, 0.5%, at 737.93.The Cboe UK 100 rose 0.7% at 815.50, the Cboe UK 250 advanced 1.1% at 18,160.09 but th

Shares in pharmaceutical firm AstraZeneca (AZN) have fallen by around 16% over the past two months after recording an all-time high at the end of August.This reflects disappointing late-stage clinical trial results for the company's antibody cancer treatment Dato-DXd, being developed with Daiichi Sankyo (4568:TYO), but the shares lost around 5% on 30 October after the company said the president of